Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMP360 in Treatment-Resistant Depression
NCT05711940Phase 3Active, not recruiting
- Sponsor
- COMPASS Pathways
- Start
- Feb 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of psilocybin in treatment-resistant depression (TRD), sponsored by COMPASS Pathways. Started Feb 2023; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05711940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05711940.